Best of ASCO® Spokane June 22, 2018

Earn up to 7.0 Contact Hours & Maintenance of Certification Points

The Association of Community Cancer Centers, Seattle Cancer Care Alliance, and Washington State Medical Oncology Society (WSMOS) are co-presenting highlights from the ASCO Annual Meeting through its licensed Best of ASCO® Meeting on Friday June 22, 6:30 AM – 4:00 PM in Spokane, Washington.

Discover practice-changing scientific and educational updates which reflect the foremost research and strategies in oncology that will directly impact patient care. You’ll engage in interactive sessions led by esteemed speakers—some of the nation's leading cancer care experts—as they share advances in state-of-the-art research and explore how these breakthroughs may impact your practice. 

Whether you were unable to attend the ASCO Annual Meeting in Chicago or are looking to network with renowned oncology researchers and thought leaders, you won't want to miss the exciting educational and collaborative opportunities this local meeting has to offer. Topics to include numerous cancer types, central nervous system tumors, biosimilars, supportive care, quality and care improvement/healthcare delivery, and more! Register for these must-attend sessions today.


This educational activity is jointly provided by AXIS Medical Education and ACCC—and is CME/CPE/CNE-certified for up to 7.0 contact hours. Meeting attendees are now able to earn Maintenance of Certification (MOC) points from the American Board of Internal Medicine (ABIM).


Discounted Hotel Rates. Best of ASCO attendees can take advantage of a 15% discount on hotel rates at three Marriott properties in Spokane. Click here to access reduced hotel rates at The Historic Davenport, The Davenport Tower, and The Davenport Grand.

Who Should Attend? Multidisciplinary clinical cancer care team members including—but not limited to—medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; oncology nurse practitioners and oncology nurses; pathologists; pharmacists; physician assistants; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

Program or registration questions? Contact ACCC at 301.984.9496, ext. 200 or via email.

Please forward this email to all members of your cancer care team who would benefit from attending this one-day conference—conveniently located to where you live!

I look forward to seeing you in Spokane!


Jennie R. Crews, MD, MMM, FACP
Medical Director and Medical Director of Research Integration, Seattle Cancer Care Alliance Network; Associate Professor of Medicine, University of Washington

President-Elect, Washington State Medical Oncology Society (WSMOS)

FDA Approval for Genentech's VENCLEXTA®

On June 8, 2018,  VENCLEXTA® venetoclax tablets) was approved by the US Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.


Genentech BioOncology® Access Solutions is your resource for access and reimbursement support after VENCLEXTA is prescribed. We can help your patients by providing: 

·       Benefits investigations (BIs)

·       Prior authorization (PA) resources

·       Information about authorized specialty pharmacies (SPs) and specialty distributors 

·       Sample billing and coding information

·       Resources for denials and appeals

·       Patient assistance options

A list of authorized specialty pharmacies and specialty distributors is available at               


For more information about Genentech BioOncology Access Solutions, please visit or call (888) 249-4918.

Genomic Health Announces TAILORx Study Results

On June 3, 2018, Genomic Health, announced that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score® results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast Recurrence Score test identified 70 percent of early-stage breast cancer patients who receive no benefit from chemotherapy, and can be effectively treated with endocrine therapy alone. Additionally, the trial established that chemotherapy may provide life-saving benefit to 30 percent of patients.

The TAILORx results will be published June 3, 2018 in The New England Journal of Medicine in conjunction with a presentation during the Plenary Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Click Here to read the entire press release from Genomic Health.

New FDA Approval for DARZALEX®

Janssen Biotech, Inc., is pleased to inform you that the US Food and Drug Administration has recently approved DARZALEX® (daratumumab) for use in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

DARZALEX® is the first and only CD38-targeted monoclonal antibody approved as monotherapy and in combination with other therapies for the treatment of multiple myeloma across various lines of therapy.

To learn more about the recent approval of DARZALEX®, view the press release or visit


The following is important information regarding a unique C-code that was recently assigned to RITUXAN HYCELA™ (rituximab/hyaluronidase human) by the Centers for Medicare & Medicaid Services (CMS). The C-code for RITUXAN HYCELA is C9467 (Injection, rituximab and hyaluronidase, 10 mg). 

The unique C-code went into effect on April 1, 2018. Payers may require its use until a permanent J-code is assigned. The permanent J-code is expected to be available for use starting on January 1, 2019. 

The C-code is used primarily in the Medicare hospital outpatient setting. Please check with your MAC to verify codes and any special billing requirements.

For more information about Genentech BioOncology Access Solutions call (888) 249‐4918 or visit

New Medicare Beneficiary Identifier (MBI)

The attached PDF provides important information about The Centers for Medicare & Medicaid (CMS) transition from the use of a Social Security number (SSN) to a Medicare Beneficiary Identifier (MBI) number, and how Genentech Access Solutions is addressing this conversion.

If you have any questions, please call Genentech Access Solutions at (866) 4ACCESS/ (866) 422-2377.

Click Below to access the PDF:

MBI Document

NEJM Article on KEYTRUDA® (pembrolizumab)

Merck is pleased to share an April 2018 New England Journal of Medicine publication that discusses KEYTRUDA® (pembrolizumab) plus chemotherapy in metastatic non-small-cell lung cancer.

Please click the link below to access the journal article. 


New FDA Approval for Opdivo® with Yervoy

On April 16, 2018, Bristol-Myers Squibb Company announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) as the first Immuno-Oncology combination therapy for previously untreated patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).1,2 In the Phase 3 CheckMate -214 clinical trial, the Opdivo + Yervoy combination demonstrated a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib. An OS benefit was observed regardless of PD-L1 expression level.1,2,3 Opdivo + Yervoy also delivered durable responses, with a higher objective response rate (ORR) compared to sunitinib.1,2 Patients in the CheckMate -214 trial received four cycles of the Opdivo + low-dose Yervoy combination, followed by Opdivo maintenance therapy.1,2 In the combination arm of the trial, 79% of patients received all four doses of Opdivo + Yervoy and went on to the Opdivo monotherapy phase.4 Flexible dosing options are available during the Opdivo maintenance phase (480 mg infused every four weeks or 240 mg infused every two weeks).

“Our goal is to provide cancer patients with medicines that have the potential to extend their lives. As the first treatment option to increase overall survival for subgroups of patients with advanced RCC compared to sunitinib, the Opdivo plus low-dose Yervoy combination helps deliver on that promise,” said Johanna Mercier, head, U.S. Commercial, Bristol-Myers Squibb. “This approval demonstrates our commitment to bringing Immuno-Oncology treatments that may improve outcomes to a broader range of RCC patients.”

Click Here to read the entire press release.